A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| 性质 | 取值 | 备注 |
|---|---|---|
| 分子类型 | 合成四十四肽 | GHRH 类似物 |
| N 端修饰 | 反式-3-己烯酰基 | 延缓酶切 |
| 分子量 | 约 5135 Da | 依序列与修饰 |
| 受体靶点 | 垂体 GHRH 受体 | 经 cAMP 通路 |
| 常见同义名 | GHRH(1-44) 类似物 | 文献通用称法 |
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Agathe Niehus, born on 28 December 1904 Gret Baumann, born on 8 February 1906 Franz Jung-Merker, born on 28 November 1908 Marianne Niehus, born on 20 September 1910 Helene Hoerni, born on 18 March 1914 None of the children continued in their father's field. The daughters, Agathe and Marianne, assisted in publishing work. During his marriage, Jung engaged in at least one extramarital relationship: with his patient and, later, fellow psychoanalyst Sabina Spielrein. A continuing affair with Toni Wolff, starting in 1910, has also been alleged. Jung confided in Freud that he had "'polygamous components' in himself" and that "'The pre-requisite of a good marriage, it seems to me, is the licence to be unfaithful'".
In enzymology, cholestenone 5alpha-reductase (EC 1.3.1.22) is an enzyme that catalyzes several chemical reactions of steroids in which a cholest-4-en-3-one is converted to the corresponding 5α-dihydrocholestan-3-one. For example, 5α-dihydroprogesterone is the product of the reduction of progesterone:
On 12 May 1926, Piłsudski staged the May Coup, a military overthrow of the civilian government mounted against President Stanisław Wojciechowski and the troops loyal to the legitimate government. Hundreds died in fratricidal fighting. Piłsudski was supported by several leftist factions who ensured the success of his coup by blocking the railway transportation of government forces.[b1] He also had the support of the conservative great landowners, a move that left the right-wing National Democrats as the only major social force opposed to the takeover.[l] Following the coup, the new government initially respected many parliamentary formalities, but gradually tightened its control and abandoned pretenses. The Centrolew, a coalition of center-left parties, was formed in 1929, and in 1930 called for the "abolition of dictatorship". In 1930, the Sejm was dissolved and a number of opposition deputies were imprisoned at the Brest Fortress. Five thousand political opponents were arrested ahead of the Polish legislative election of 1930, which was rigged to award a majority of seats to the pro-government Nonpartisan Bloc for Cooperation with the Government (BBWR).
If silver or white (Blanco) tequila is the desired final product, distillation is the final process it undergoes. Rested (Reposado) or aged (Añejo) tequila must be matured in 200-liter (or larger) white oak barrels for at least two months for the former and 12 months for the latter. The newest category of tequila classification, extra añejo, must be aged for at least three years in oak barrels. There are, however, more than 50 different companies producing tequila in the Mexican state of Jalisco, with different maturation times according to the variety of tequila and desired quality of the final product. All companies producing tequila have their aging processes regulated and fiscalized by the Mexican government.
Fumarate, produced from the purine nucleotide cycle, is an intermediate of TCA cycle and enters the mitochondria by converting into malate and utilizing the malate shuttle where it is converted into oxaloacetic acid (OAA). During exercise, OAA either enters into TCA cycle or converts into aspartate in the mitochondria. As the purine nucleotide cycle produces ammonia (see below in ammonia synthesis), skeletal muscle needs to synthesize glutamate in a way that does not further increase ammonia, and as such the use of glutaminase to produce glutamate from glutamine would not be ideal. Also, plasma glutamine (released from the kidneys) requires active transport into the muscle cell (consuming ATP). Consequently, during exercise when the ATP reservoir is low (ADP>ATP), glutamate is produced from branch-chained amino acids (BCAAs) and α-ketoglutarate, as well as from alanine and α-ketoglutarate. Glutamate is then used to produce aspartate. The aspartate enters the purine nucleotide cycle, where it is used to convert IMP into S-AMP.
Sources: en.wikipedia.org
Finance and Provisions – responsible for supplying provisions and other necessities to the guerrillas. Organization and Communication – responsible for coordinating the relationship between the leadership and its support base. Military Committee – responsible for the guerrilla's army regiments. Intelligence and Education – responsible for political education and information on enemy activity, and United Front – responsible for propaganda and mobilizing support. The Huk military structure was modeled after the Chinese Red Army. It was composed of squads and platoons, consisting of 100 officers and men, which formed a squadron. Two squadrons formed one battalion, and two battalions formed a regiment. These numbers were not always followed though: For example, Squadron 8, based in Talavera, Nueva Ecija, had twelve squads, each with a dozen men.
=== Random selenocystine === Just as selenomethionine can be randomly incorporated into proteins, selenocystine can also be mistakenly attached to tRNACys by cysteinyl-tRNA synthetase and incorporated into proteins in lieu of cystine. This causes considerable toxicity. A variant synthase that can distinguish between Cys and Sec helps reduce toxicity. This toxicity may be one reason for the existence of a rather complicated pathway of selenocysteine biosynthesis and specific incorporation into selenoproteins (described above), which avoids the occurrence of the free amino acid as intermediate. Due to this pathway, even if a selenocysteine-containing selenoprotein is taken up in the diet and used as selenium source, the selenocysteine residue is not reused directly.
Ubiquitin is a small (8.6 kDa) regulatory protein found in most tissues of eukaryotic organisms, i.e., it is found ubiquitously. It was discovered in 1975 by Gideon Goldstein and further characterized throughout the late 1970s and 1980s. Four genes in the human genome code for ubiquitin: UBB, UBC, UBA52 and RPS27A. The addition of ubiquitin to a substrate protein is called ubiquitylation (or ubiquitination or ubiquitinylation). Ubiquitylation affects proteins in many ways: it can mark them for degradation via the 26S proteasome, alter their cellular location, affect their activity, and promote or prevent protein interactions. Ubiquitylation involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. The result of this sequential cascade is to bind ubiquitin to lysine residues on the protein substrate via an isopeptide bond, cysteine residues through a thioester bond; serine, threonine, and tyrosine residues through an ester bond; or the amino group of the protein's N-terminus via a peptide bond. The protein modifications can be either a single ubiquitin protein (monoubiquitylation) or a chain of ubiquitin (polyubiquitylation). Secondary ubiquitin molecules are always linked to one of the seven lysine residues or the N-terminal methionine of the previous ubiquitin molecule.
Professor at the University of Groningen. Rachel Mamlok-Naaman, Israeli chemist, specialized in chemistry education Corine Mathonière, French materials chemist studying molecular magnetism, spin crossover molecules, and coordination chemistry Catherine J. Murphy, American chemist Nga Lee (Sally) Ng, atmospheric chemist studying particulates and their effects on air quality, climate, and human health Sarah O'Connor, American plant synthetic biologist working in England Kimberly Prather, American atmospheric chemist whose research contributed to understanding of atmospheric aerosols and their impact on air quality, climate, and human health Gillian Reid, British inorganic chemist. President elect (2020-present) and present (2022-present) of the Royal Society of Chemistry. Professor at the University of Southampton. Sarah E Reisman, American organic chemist Magdalena Titirici, materials chemist focusing on sustainable materials for energy applications. Professor at Imperial College London. Claudia Turro, American inorganic chemist who studies light-initiated reactions of metal complexes with application to disease treatment and solar energy conversion. Seble Wagaw, American process chemist and pharma exec Marcey Lynn Waters, American chemical biologist and supramolecular chemist Jenny Y Yang, American chemist and clean energy researcher at UCI Wendy Young, American medicinal chemist and pharmaceutical executive. Chair of ACS Medicinal Chemistry Division (2017). Jaqueline Kiplinger, American chemist working at the Los Alamos National Laboratory
Sources: en.wikipedia.org
=== Other invasive electrical methods === Auditory brainstem implant, which provides a sense of sound to a person who cannot use a cochlear implant due to a damaged or missing cochlea or auditory nerve Functional electrical stimulation (FES) Vagus nerve stimulation (VNS) Hypoglossal nerve stimulation, an option for some patients who have obstructive sleep apnea Percutaneous tibial nerve stimulation (PTNS) for the treatment of incontinence. Peripheral nerve stimulation (PNS, which refers to stimulation of nerves beyond the spine or brain, and may be considered to include occipital or sacral nerve stimulation) Occipital nerve stimulation (ONS) Sacral nerve stimulation (SNS) / sacral neuromodulation (SNM)
Present data show that (R)-phenylpiracetam increases motivation, i.e., the work load, which animals are willing to perform to obtain more rewarding food. At the same time consumption of freely available normal food does not increase. Generally this indicates that (R)-phenylpiracetam increase motivation [...] The effect of (R)-phenylpiracetam is much stronger than that of methylphenidate and amphetamine.
=== Inositol depletion hypothesis === Lithium treatment has been found to inhibit the enzyme inositol monophosphatase, involved in degrading inositol monophosphate to inositol required in PIP2 synthesis. This leads to lower levels of inositol triphosphate, created by decomposition of PIP2. This effect has been suggested to be further enhanced with an inositol triphosphate reuptake inhibitor. Inositol disruptions have been linked to memory impairment and depression. It is known with good certainty that signals from the receptors coupled to the phosphoinositide signal transduction are affected by lithium. Myo-inositol is also regulated by the high affinity sodium mI transport system (SMIT). Lithium is hypothesized to inhibit mI entering the cells and mitigate the function of SMIT. Reductions of cellular levels of myo-inositol results in the inhibition of the phosphoinositide cycle.
Sources: en.wikipedia.org
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。
作为多肽，它难以通过胃肠道吸收，通常需要注射给药。口服会因消化酶降解而失去活性，因此文献中讨论的都是注射途径。
公开研究多集中在内脏脂肪、体成分分布以及与生长激素轴相关的代谢指标。长期安全性和在普通人群中的适用性尚缺乏一致结论。
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.